CytoTools AG has received the preliminary results of the test series with the active substance DPOCL, carried out in cooperation with the Institute for Medical Virology at the University Hospital Frankfurt. The test results confirm the clearly virucidal ("virus-killing") effect of the active ingredient on the COVID-19-triggering SARS-CoV-2 pathogen. In the cell culture experiments of the university working group Medical Virology, the efficacy of DPOCL on the virus SARS-CoV-2 was investigated in combination with human CaCo-2 cells. A dose-dependent effect was found, which confirmed a more than 90% efficacy with the highest dose. Thus a virucidal efficacy of DPOCL on the virus SARS-CoV-2 has been proven. The test results underline the very good efficacy of DPOCL and, together with already available data on DPOCL, suggest that the drug is well tolerated. With the pre-clinical data of DPOCL already available, the first human trials can now be started shortly. In this human study, the use of DPOCL as a multiple daily inhalation component with physiological saline solution via commercially available inhalers will be investigated in order to bring the product to market quickly in an easily applicable form. In the company's internal test series with commercially available inhalers, the nebulization of DPOCL in saline solution has already been successfully tested. The company therefore assumes that the positive results can also be replicated in the human study that is now being conducted. This would allow the virus to be controlled directly in the lungs or in the bronchial region and the upper respiratory tract, i.e. at the virus' entry barrier into the body, at a very early stage. The good tolerability of the drug solution offers the advantage that comparatively complication-free treatment can be started at a very early stage of an infection. DPOCL is already approved as a wound healing product for the indication diabetic foot in the Indian market and is currently in the beginning of a Phase III clinical trial in Europe. In addition to the effect of DPOCL on the SARS-CoV-2 virus, the Institute of Medical Virology is also investigating its virucidal effect on influenza viruses. Should the results prove a similarly high efficacy, DPOCL could be a fundamentally new therapy for viral influenza infections - beyond the COVID-19 pandemic.